Hvorhen meddeles det, på nett først eller fra selskapene?
selskapet får vite det dagen etter møte. Møtereferat slippes på nett ca 1 uke etter møte
1 Like
Det ble sagt på Q2, 29:23 ut i webcasten stiller JE spørsmålet.
2 Likes
“In recent years, targeted radionuclide therapy has been moving from an exotic treatment modality for a very few patients to a mainstream modality. ”
“Lutetium-177 seems destined to find important applications in the personalized therapy of patients using low-abundance gamma photons for diagnosis. This paradigm, when properly enforced, would not only provide a clear understanding of the disease following its detection and progression, but also provide vital clues for making decisions about individualized treatments. Administering suitable 177Lu-labeled radiopharmaceuticals in their required doses and providing personalized treatment planning constitute a major step forward to meet the challenges of personalized medicine. Implementation of this regimen is likely to trigger profound structural changes in the treatment strategy and potentially to create a situation where treatments can be tailored to individual patient-specific diseases.”
3 Likes
Bull
Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast
Oslo, Norway, 17 October 2018
Nordic Nanovector ASA (OSE: NANO) announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previously scheduled for Tuesday, 21 November), and will host a results presentation and webcast on the same day (details will be announced nearer the time).
During this presentation, the Company will present updated clinical results from the LYMRIT 37-01 trial with Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphoma patients. These results will be published on 1 November in an abstract* that will be presented in a poster at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018).
As a consequence of the change in date of the third quarter 2018 results presentation, the Company will enter its two-week `quiet period’ starting on the 23 October 2018.
In addition, the Company has decided it will not continue hosting separate presentations of the results in Norwegian.
*ASH abstract
Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin’s lymphoma (NHL) - Analysis with 6-month follow-up
Authors: A. Kolstad, et al.
The abstract will be published on 1 November 2018 at 09:00am Eastern time at http://www.hematology.org/Annual-Meeting/
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20181017.Cision.20181016:BIT:2562:0
6 Likes
Financial calendar
Financial calendar for Nordic Nanovector ASA
FINANCIAL YEAR 2018
06.11.2018 - Quarterly Report - Q3
27.02.2019 - Quarterly Report - Q4FINANCIAL YEAR 2019
23.05.2019 - Quarterly Report - Q1
22.08.2019 - Half-yearly Report
21.11.2019 - Quarterly Report - Q325.04.2019 - Annual General Meeting
The dates are subject to change. The time and location of the
presentations will be announced in due time.This information is published pursuant to the requirements set out in the
Continuing obligations.Ekstern link: http://www.newsweb.no/index.jsp?messageId=461404
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20181017.OBI.20181017S12
Nordic Nanovector - Financial Calendar
Oslo, Norway, 17 October 2018
FINANCIAL YEAR 2018
Quarterly Report - Q3 06.11.2018 (changed from 21.11.2018)
Quarterly Report - Q4 27.02.2019
FINANCIAL YEAR 2019
Annual General meeting 25.04.2019
Quarterly Report - Q1 23.05.2019
Half-yearly Report 22.08.2019
Quarterly Report - Q3 21.11.2019
The dates are subject to change. The time and location of the presentations will be announced in due time.
This information is published pursuant to the requirements set out in the Continuing obligations.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
Ekstern link: http://news.cision.com/nordic-nanovector/r/nordic-nanovector—financial-calendar,c2646221
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20181017.Cision.20181017:BIT:3021:0
Hmm, noe de ønsker å dele som de ikke har lyst til å holde på lenger?
5 Likes
Tenkte det samme! 
3 Likes
Håper det!
Den god-feelingen begynner å komme tilbake. Dette gir nok en del vann på spekulasjonsmølla!
2 Likes
Hm… Kan slå begge veier det her. Enten så viser det seg at Arm4 dataene er så rævva at Nano kun kjører videre med 15/40, eller så er 20/100 overlegen 15/40.
Begge er jo bull! 15/40 fungerer jo dritbra!
1 Like
15/40 eller 20/100 er jeg way beyond, ikke tema.
2 Likes
Nano har jo besluttet to armer i samarbeid med FDA, for å h best mulig grunnlag- det har de nok ikke på 12-15 pasienter. For dårlig sammenligningsgrunnlag er vel en av de største årsakene til avslag på godkjenning.
1 Like
Det er 22 pasienter som har fått 20/100.
Mitt svar var i forhold til dem som fikk vann på spekulasjonsmøllen;)
Det kan like gjerne være noe negativt som positivt, det har jeg lært etter 3 år som aksjonær i Nano.
2 Likes
Flere tanker her:
-
Utrolig bra at selskapet veldig aktivt forbereder markedet på at abstractet kommer 1. november, i fjor ble det jo helt kaos.
Jeg hadde veldig ønsket meg at selskapet tok dette enda lenger, og fikk børsen til å pause aksjen noen timer akkurat rundt slippet av aksjen. -
Når de velger få flytte datoen for Q3 så tenker jeg at det kan bety to ting:
A: De husker kaoset i fjor, og ønsker å gi seg selv best mulig mulighet for å supplere med informasjon.
_editerte vekk noe her http://www.hematology.org/Annual-Meeting/Abstracts/3282.aspx -
De har tydeligvis ikke hatt nok folk til å besøke de norskspråklige presentasjonene til at det var verd det.
5 Likes
Vel, du prøver å holde så lenge som mulig på bad news (f.eks Costas avgang og medfølgende info retorikk) mens good news fremskynder du for å få kursen over 200 dg. glidende snitt og nedtrenden fra ATH (som i følge @Savepig nå ligger på 61 ) - jeg kjøper nok litt i dag (første gang siden før sommerferien ).
Hæ???
Til informasjon så sitter jeg lastet til ripen med Nano aksjer, så håper selvsagt at det er good news. Har sluttet å bli euforisk av spekulasjoner;)